ContraFect Corporation (CFRXQ)

OTCMKTS: CFRXQ · Delayed Price · USD
0.0222
0.00 (0.00%)
Mar 28, 2024, 4:00 PM EDT - Market closed

Company Description

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States.

Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus.

The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections.

It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections.

In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients.

Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis.

The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens.

ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York. On December 4, 2023, ContraFect Corporation filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

ContraFect Corporation
ContraFect logo
Country United States
Founded 2008
IPO Date Jul 29, 2014
Industry Biotechnology
Sector Healthcare
Employees 23
CEO Roger Pomerantz

Contact Details

Address:
28 Wells Avenue, 3rd Floor
Yonkers, New York 10701
United States
Phone 914-207-2300

Stock Details

Ticker Symbol CFRXQ
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001478069
SIC Code 2834

Key Executives

Name Position
Michael Messinger CPA Chief Executive Officer, President, Chief Financial Officer and Principal Accounting Officer
Natalie Bogdanos J.D. General Counsel, Corporate Secretary and Data Protection Officer
Matthew Salamone P.H.R., SPHR Vice President of Human Resources
Dr. Gary Woodnutt Senior Vice President of Translational Sciences and Preclinical Development
Dr. William Garrett Nichols M.D., M.S. Interim Chief Medical Officer

Latest SEC Filings

Date Type Title
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Dec 27, 2023 25-NSE Filing
Dec 5, 2023 8-K Current Report
Nov 15, 2023 8-K Current Report
Nov 14, 2023 10-Q Quarterly Report
Nov 8, 2023 8-K Current Report
Nov 3, 2023 424B3 Prospectus
Nov 2, 2023 EFFECT Notice of Effectiveness
Oct 30, 2023 S-1 General form for registration of securities under the Securities Act of 1933
Oct 24, 2023 S-1 General form for registration of securities under the Securities Act of 1933